Cellistic, Sarah Legrain

The main objective of the MacroTwin project is to establish a scaled iPSC-macrophage manufacturing platform and create a digital twin thereof for use in allogeneic cell therapy product development and manufacturing. The project will be based on a collaboration between Celyntra Therapeutics (working as Cellistic), a cell therapy Contract Development Manufacturing Organisation (CDMO) service provider with unique expertise in iPSC biology, immunology, and bioprocess development, Pharmalex, a leader in statistics, data science and analytics services for biopharmaceutical and medical product development, and the Institute of Condensed Matter and Nanosciences of UCLouvain which will introduce expertise on biomaterials necessary for bioprocess development.
The MacroTwin project aims to simplify cell therapy development pipelines through technologies such as data analytics, machine learning, and artificial intelligence to construct a digital twin, thus enhancing efficiency and productivity in biopharmaceutical manufacturing and contributing to the broader digitalisation of the industry. The collaboration is expected to create new positions, grow existing teams, and ultimately improve patient outcomes, lower cell therapy healthcare costs and strengthen the ATMP value chain in Wallonia and Belgium, positioning the region as a key player in biotech and pharmaceutical sectors globally.
Connect with us